drugset / Trial / NCT01872702

Summary

The overall aim of this study is two fold: 1. to pilot targeted chemo-elimination of plasmodium falciparum malaria in known areas of artemisinin resistance in South East Asia. 2. to understand the micro-epidemiology of malaria in these areas; chiefly, the prevalence and importance to on-going transmission of sub-clinical p.f malaria infections.

Timeline

Start
2013-04
Primary completion
2017-07
Completion
2017-07

Outcome

Met primary endpoint

paper The primary outcome, P. falciparum incidence in the 12 months after MDA, was lower in intervention villages (1.5/1000 PY vs 37.1/1000 PY; PMID 29522113 ↗

paper The primary outcome, P. falciparum prevalence by month 3 (M3), fell by 92% (from 5.1% [171/3,340] to 0.4% [12/2,828]) in early MDA villages PMID 30768615 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject ARTENIMOL Small molecule — —
Subject Primaquine Small molecule 0.25 mg/kg —
Subject piperaquine Small molecule — —